NURIX THERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- NURIX THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2026-02-28 was $17.99M.
- NURIX THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2024-05-31 was $188.73M.
- NURIX THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2022-08-31 was $19.33M.
- NURIX THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2021-05-31 was $150.16M.
- NURIX THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2025 was $234.39M, a 24.19% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2024 was $188.73M.
- NURIX THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2022 was $19.33M, a 87.13% decline from fiscal 2021.
- NURIX THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2021 was $150.16M, a 31.17% decline from fiscal 2020.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-02-28 | $17.99M 10-Q · filed 2026-07-09 | |
| 2025-11-30 | $234.39M 10-K · filed 2026-01-28 | |
| 2024-11-30 | $188.73M 10-K · filed 2026-01-28 | |
| 2024-05-31 | $188.73M 10-Q · filed 2025-10-09 | |
| 2022-11-30 | $19.33M 10-K · filed 2024-02-15 | |
| 2022-08-31 | $19.33M 10-Q · filed 2023-10-12 | |
| 2021-11-30 | $150.16M 10-K · filed 2023-02-09 | |
| 2021-05-31 | $150.16M 10-Q · filed 2022-10-06 | |
| 2020-11-30 | $218.15M 10-K · filed 2022-01-28 | |
| 2020-08-31 | $218.14M 10-Q · filed 2021-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |